ROS1 fusions in Chinese patients with non-small-cell lung cancer

Cai, Weiping; Li, X.; Su, Chunxia; Fan, Lihong; Zheng, Li-Mou; Fei, K.; Zhou, C.; Manegold, Christian; Schmid-Bindert, Gerald

doi:10.1093/annonc/mdt071

Cited by 70 publications

(84 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30,37 However, this association has not been consistently observed across studies. 34 Other clinical characteristics, such as younger age, female sex, and non-Asian ethnicity, have been associated with ROS1 rearrangement in isolated studies only. 30,31,35 Therefore, clinical characteristics should not be used to either select or exclude patients from testing for ROS1 rearrangements.…”

Section: Expert Consensus Opinionmentioning

confidence: 99%

“…This recommendation is evidence based and supported by 9 studies, 30e38 6 of which informed on the association between ROS1 rearrangement and patient or tumor characteristics 30,31,34e37 and consisted of 1 prospective cohort study (PCS), 35 1 prospective-retrospective cohort study (PRCS), 31 and 4 retrospective cohort studies (RCSs). 30,34,36,37 The 3 remaining studies assessed clinical outcomes of patients treated with the ROS1-targeted therapy crizotinib 32,33,38 and included 1 nonrandomized clinical trial 33 and 3 RCSs. 32,38 All included studies were assessed for quality and none were found to have methodologic flaws that would raise concerns about the studies' findings (SDC Table 6).…”

Section: Strong Recommendationmentioning

confidence: 99%

“…Although relatively rare, accounting for <2% of nonesmall cell lung carcinomas 30,31,34 and 2% to 3% of lung adenocarcinomas, 30,34,35 structural rearrangements involving the ROS1 gene generate an oncogenic fusion that can be treated successfully with targeted inhibitors. A single phase I clinical trial of 50 NSCLC patients demonstrated that the presence of a ROS1 rearrangement by FISH or RT-PCR predicts response to targeted inhibition using crizotinib, with a response rate of 72% and median progression-free survival of 19.2 months.…”

Section: Strong Recommendationmentioning

confidence: 99%

See 2 more Smart Citations

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Aung

Donald

Ellison

et al. 2014

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

Context: In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to set standards for the molecular analysis of lung cancers to guide treatment decisions with targeted inhibitors. New evidence has prompted an evaluation of additional laboratory technologies, targetable genes, patient populations, and tumor types for testing. Objective: To systematically review and update the 2013 guideline to affirm its validity; to assess the evidence of new genetic discoveries, technologies, and therapies; and to issue an evidence-based update. Design: The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology convened an expert panel to develop an evidence-based guideline to help define the key questions and literature search terms, review abstracts and full articles, and draft recommendations. Results: Eighteen new recommendations were drafted. The panel also updated 3 recommendations from the 2013 guideline. Conclusions: The 2013 guideline was largely reaffirmed with updated recommendations to allow testing of cytology samples, require improved assay sensitivity, and recommend against the use of

show abstract

Section: Expert Consensus Opinionmentioning

confidence: 99%

Section: Strong Recommendationmentioning

confidence: 99%

Section: Strong Recommendationmentioning

confidence: 99%

See 1 more Smart Citation

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Aung

Donald

Ellison

et al. 2014

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…ROS1 fusions are widespread in never-smokers with a histological diagnosis of adenocarcinoma (54). In patients with NSCLC, chromosomal translocations have been identified by ROS1-solute carrier family 34 member 2 (SLC34A2) and ROS1-cluster of differentiation 74 (CD74) fusions, which involve the fusion of the 5' region of SLC34A2 with the 3' region of ROS1 and the fusion of the 5' region of CD74 with the 3' region of ROS1, respectively (55).…”

Section: Molecular Biology Of Lung Cancermentioning

confidence: 99%

Familial risk for lung cancer

2016

View full text Add to dashboard Cite

Abstract. Lung cancer, which has a low survival rate, is a leading cause of cancer-associated mortality worldwide. Smoking and air pollution are the major causes of lung cancer; however, numerous studies have demonstrated that genetic factors also contribute to the development of lung cancer. A family history of lung cancer increases the risk for the disease in both smokers and never-smokers. This review focuses on familial lung cancer, in particular on the familial aggregation of lung cancer. The development of familial lung cancer involves shared environmental and genetic factors among family members. Familial lung cancer represents a good model for investigating the association between environmental and genetic factors, as well as for identifying susceptibility genes for lung cancer. In addition, studies on familial lung cancer may help to elucidate the etiology and mechanism of lung cancer, and may identify novel biomarkers for early detection and diagnosis, targeted therapy and improved prevention strategies. This review presents the aetiology and molecular biology of lung cancer and then systematically introduces and discusses several aspects of familial lung cancer, including the characteristics of familial lung cancer, population-based studies on familial lung cancer and the genetics of familial lung cancer.

show abstract

“…Such rearrangements have been identified in approximately 1%–2% of NSCLC patients using different genotyping techniques (Table 3). 47,48 Several recent studies used whole-transcriptome and whole-genome sequencing to detect ROS1 rearrangements, and several novel fusion partners were identified 47,48. Such methods are not yet readily applicable in the clinic.…”

Section: Prevalence Of Driver Mutations In Lung Cancersmentioning

confidence: 99%

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

Gou¹,

Wu²

2014

LCTT

View full text Add to dashboard Cite

Lung cancer is a leading cause of cancer-related mortality worldwide and in the People’s Republic of China. Recently, the pathological proportions of the various forms of lung cancer have changed. A shift to a preponderance of adenocarcinoma at the expense of squamous cell carcinoma is observable. Treatment decisions have historically been based on tumor histology, and evolution of our molecular understanding of cancer has led to development of targeted therapeutic agents. It is essential to further understand mutations that drive cancer development (driver mutations) in relevant genes and their effects on cancer cell proliferation and survival. The epidemiology of lung cancer in the People’s Republic of China has been extensively reviewed elsewhere. However, molecular epidemiological data from mainland China are scarce. Consequently, we herein review the prevalence of driver mutations in Chinese patients.

show abstract

ROS1 fusions in Chinese patients with non-small-cell lung cancer

Abstract: ROS1 fusions occurred in ∼2.0% of Chinese patients with NSCLC and had no specific clinicopathological feature. ROS1 fusion-negative patients may have a better survival than ROS1 fusion-positive patients.

Cited by 70 publications

References 26 publications

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Familial risk for lung cancer

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

Contact Info

Product

Resources

About

ROS1 fusions in Chinese patients with non-small-cell lung cancer

Abstract: ROS1 fusions occurred in ∼2.0% of Chinese patients with NSCLC and had no specific clinicopathological feature. ROS1 fusion-negative patients may have a better survival than ROS1 fusion-positive patients.

Cited by 70 publications

References 26 publications

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Familial risk for lung cancer

Prevalence of driver mutations in non-small-cell lung cancers in the People&rsquo;s Republic of China

Contact Info

Product

Resources

About

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China